Literature DB >> 30988379

Daratumumab is a safe and effective rescue therapy for multiple myeloma patients who relapse after allo-HSCT.

Ana Pilar Gonzalez-Rodriguez1, Lucia Lopez-Corral2, David Fernando Moreno Fajardo3, Ana Julia Gonzalez-Huerta4, Pilar Palomo4, Arantxa Bermudez5, Teresa Zudaire Ripa6, Patricia Santos-Diaz7, Soledad Gonzalez-Muñiz4, Joud Zanabilli4, Ana Jimenez Ubieto8, Felipe de Arriba9, Mario Arnao-Herraiz10, Christian Sordo-Bahamonde11, Alejandro López-Soto11, Segundo Gonzalez11, Laura Rosiñol3, María-Victoria Mateos2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 30988379     DOI： 10.1038/s41409-019-0525-1

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN： 0268-3369            Impact factor:   5.483


× No keyword cloud information.
  2 in total

1.  Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial.

Authors:  Sagar Lonial; Brendan M Weiss; Saad Z Usmani; Seema Singhal; Ajai Chari; Nizar J Bahlis; Andrew Belch; Amrita Krishnan; Robert A Vescio; Maria Victoria Mateos; Amitabha Mazumder; Robert Z Orlowski; Heather J Sutherland; Joan Bladé; Emma C Scott; Albert Oriol; Jesus Berdeja; Mecide Gharibo; Don A Stevens; Richard LeBlanc; Michael Sebag; Natalie Callander; Andrzej Jakubowiak; Darrell White; Javier de la Rubia; Paul G Richardson; Steen Lisby; Huaibao Feng; Clarissa M Uhlar; Imran Khan; Tahamtan Ahmadi; Peter M Voorhees
Journal:  Lancet       Date:  2016-01-07       Impact factor: 79.321

2.  Cytomegalovirus Reactivation in a Patient With Extensively Pretreated Multiple Myeloma During Daratumumab Treatment.

Authors:  Kristine A Frerichs; Patricia W C Bosman; Inger S Nijhof; Sonja Zweegman; Niels W C J van de Donk
Journal:  Clin Lymphoma Myeloma Leuk       Date:  2018-10-13
  2 in total
  1 in total

1.  Prognostic Factors for Postrelapse Survival after ex Vivo CD34+-Selected (T Cell-Depleted) Allogeneic Hematopoietic Cell Transplantation in Multiple Myeloma.

Authors:  Alexandra Gomez-Arteaga; Gunjan L Shah; Raymond E Baser; Michael Scordo; Josel D Ruiz; Adam Bryant; Parastoo B Dahi; Arnab Ghosh; Oscar B Lahoud; Heather J Landau; Ola Landgren; Brian C Shaffer; Eric L Smith; Guenther Koehne; Miguel-Angel Perales; Sergio A Giralt; David J Chung
Journal:  Biol Blood Marrow Transplant       Date:  2020-07-23       Impact factor: 5.742
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.